News
This twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.
The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need - FDA approval paves the way for the ...
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
General, Winnie Byanyima, has called for a drastic and transparent reduction in the cost of lenacapavir, a twice-yearly ...
The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback